302 related articles for article (PubMed ID: 32042194)
21. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
22. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
[No Abstract] [Full Text] [Related]
23. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
24. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma.
Wang G; Wu M; Durham AC; Radaelli E; Mason NJ; Xu X; Roth DB
PLoS One; 2020; 15(3):e0229728. PubMed ID: 32210430
[TBL] [Abstract][Full Text] [Related]
25. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
[TBL] [Abstract][Full Text] [Related]
26. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
[TBL] [Abstract][Full Text] [Related]
27. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients.
Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
Cancer Sci; 2020 Oct; 111(10):3893-3901. PubMed ID: 32662546
[TBL] [Abstract][Full Text] [Related]
28. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients.
Wong S; Ehrhart EJ; Stewart S; Zismann V; Cawley J; Halperin R; Briones N; Richter K; Sivaprakasam K; Perdigones N; Contente-Cuomo T; Facista S; Trent JM; Murtaza M; Khanna C; Hendricks WPD
PLoS One; 2022; 17(7):e0264986. PubMed ID: 35867969
[TBL] [Abstract][Full Text] [Related]
29. Whole exome sequencing of rare aggressive breast cancer histologies.
Dieci MV; Smutná V; Scott V; Yin G; Xu R; Vielh P; Mathieu MC; Vicier C; Laporte M; Drusch F; Guarneri V; Conte P; Delaloge S; Lacroix L; Fromigué O; André F; Lefebvre C
Breast Cancer Res Treat; 2016 Feb; 156(1):21-32. PubMed ID: 26907767
[TBL] [Abstract][Full Text] [Related]
30. A patient-researcher partnership for rare cancer research.
Staniszewka S
Nat Med; 2020 Feb; 26(2):164-165. PubMed ID: 32042195
[No Abstract] [Full Text] [Related]
31. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.
Italiano A; Chen CL; Thomas R; Breen M; Bonnet F; Sevenet N; Longy M; Maki RG; Coindre JM; Antonescu CR
Cancer; 2012 Dec; 118(23):5878-87. PubMed ID: 22648906
[TBL] [Abstract][Full Text] [Related]
32. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
33. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
34. Treatment Monitoring of a Patient with Synchronous Metastatic Angiosarcoma and Breast Cancer Using ctDNA.
Vannas C; Escobar M; Österlund T; Andersson D; Mouhanna P; Soomägi A; Molin C; Wennergren D; Fagman H; Ståhlberg A
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612833
[TBL] [Abstract][Full Text] [Related]
35. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
36. Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
Aparicio T; Svrcek M; Henriques J; Afchain P; Lièvre A; Tougeron D; Gagniere J; Terrebonne E; Piessen G; Legoux JL; Lecaille C; Pocard M; Gornet JM; Zaanan A; Lavau-Denes S; Lecomte T; Deutsch D; Vernerey D; Puig PL
Int J Cancer; 2021 Apr; 148(7):1731-1742. PubMed ID: 33186471
[TBL] [Abstract][Full Text] [Related]
37. Mutation of the PTEN gene in a human hepatic angiosarcoma.
Tate G; Suzuki T; Mitsuya T
Cancer Genet Cytogenet; 2007 Oct; 178(2):160-2. PubMed ID: 17954274
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Moon WK; Chen HH; Shin SU; Han W; Chang RF
Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
[TBL] [Abstract][Full Text] [Related]
39. Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck.
Chen HB; Gong XY; Li W; Chen DS; Zhao LL; Li S; Xiao MZ; Cheng L; Chen X
Oral Oncol; 2021 Oct; 121():105436. PubMed ID: 34371452
[TBL] [Abstract][Full Text] [Related]
40. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
